Scientific Literature Search

Source record

Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease.

Rautio J.

J Med Chem · 2012-10-18

DOI: 10.1021/jm301460xPMID: 23078245

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Barrett MJ, Hagenah J, Dhawan V, Peng S, Stanley K, Raymond D, Deik A, Gross SJ, Schreiber-Agus N, Mirelman A, Marder K, Ozelius LJ, Eidelberg D, Bressman SB, Saunders-Pullman R, LRRK2 Ashkenazi Jewish Consortium.

Parkinsonism Relat Disord · 2012-10-10

DOI: 10.1016/j.parkreldis.2012.09.007PMID: 23062841

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

Greggio E.

Biochem Soc Trans · 2012-10-01

DOI: 10.1042/bst20120054PMID: 22988865

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Xiong Y, Dawson VL, Dawson TM.

Biochem Soc Trans · 2012-10-01

DOI: 10.1042/bst20120093PMID: 22988868

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations.

Mills RD, Mulhern TD, Cheng HC, Culvenor JG.

Biochem Soc Trans · 2012-10-01

DOI: 10.1042/bst20120088PMID: 22988870

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

Belluzzi E, Greggio E, Piccoli G.

Biochem Soc Trans · 2012-10-01

DOI: 10.1042/bst20120124PMID: 22988874

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.

Bravo-San Pedro JM, Gómez-Sánchez R, Niso-Santano M, Pizarro-Estrella E, González-Polo RA, Fuentes JM.

Biochem Soc Trans · 2012-10-01

DOI: 10.1042/bst20120095PMID: 22988877

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Neuronal autophagy, α-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain.

Plotegher N, Civiero L.

J Neurosci · 2012-10-01

DOI: 10.1523/jneurosci.3588-12.2012PMID: 23100407

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson's disease in a Han Chinese population from Southern Mainland China.

Fu X, Zheng Y, Hong H, He Y, Zhou S, Guo C, Liu Y, Xian W, Zeng J, Li J, Liu Z, Chen L, Pei Z.

Parkinsonism Relat Disord · 2012-09-13

DOI: 10.1016/j.parkreldis.2012.08.007PMID: 22981185

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease.

Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A, Chinnery PF, Burn DJ, Clarke CE, Marion MH, Lewthwaite AJ, Nicholl DJ, Wood NW, Morrison KE, Williams-Gray CH, Evans JR, Sawcer SJ, Barker RA, Wickremaratchi MM, Ben-Shlomo Y, Williams NM, Morris HR.

Mov Disord · 2012-09-06

DOI: 10.1002/mds.25132PMID: 22956510

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Ray S, Liu M.

Future Med Chem · 2012-09-01

DOI: 10.4155/fmc.12.110PMID: 22924508

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.

Abdel-Magid AF.

ACS Med Chem Lett · 2012-07-27

DOI: 10.1021/ml300200pPMID: 24900536

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

1.220 articles found

Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease.

Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations.

Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.

Neuronal autophagy, α-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain.

LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson's disease in a Han Chinese population from Southern Mainland China.

Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease.

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.

Filters